acyl-CoA cholesterol acyltransferase inhibitor/diacylglycerol acyltransferase inhibitor/apolipoprotein-A1 stimulator (Kyoto)

N/A

Report date: 2025/03/14 20:00:48

NME

Base Information

Drug Nameacyl-CoA cholesterol acyltransferase inhibitor/diacylglycerol acyltransferase inhibitor/apolipoprotein-A1 stimulator (Kyoto)

Drug Alias NameACAT inhibitor/DGAT inhibitor/Apolipoprotein-A1 stimulator (Kyoto)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionAcyl coenzyme A:cholesterol acyltransferase 2 inhibitorsDiacylglycerol O-acyltransferase 1 inhibitorsDiacylglycerol O-acyltransferase 2 inhibitors +[5]

TargetsDiacylglycerol O-acyltransferase 1Acyl coenzyme A:cholesterol acyltransferase 1Apolipoprotein A-I +[5]

Therapy Area/IndicationsAtherosclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesKyoto Pharmaceutical Industries Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesKyoto Pharmaceutical Industries Ltd

Active IndicationsN/A

Inactive IndicationsAtherosclerosis

Other Information

ATC CodeN/A